Validation of Copy Number Changes by MLPA as Predictors of Relapse in Wilms Tumor
- To analyze 250 favorable-histology Wilms tumor (FHWT) samples from patients registered
on NWTS4 for gain of 1q and 15q, and loss of 1p, 16q, 17p, and 22q by subtelomeric
multiplex ligation-dependent probe amplification (MLPA), and to determine their
association with relapse-free and overall survival.
- To develop a robust multiplex MLPA test using multiple synthesized probes to those
targets identified as significantly associated with relapse in Aim 1.
- To validate the multiplex MLPA test designed and tested in Aim 2 on an independent set
of 1727 FHWT and 250 anaplastic WT registered on NWTS-5.
OUTLINE: Archived DNA samples are analyzed for gain of 1q and 15q, and loss of 1p, 16q, 17p,
and 22q by MLPA. Assay results are then researched for accuracy, clinical validity,
sensitivity, precision, and potential analytical interferences.
Validation of copy number changes (gain of 1q and 15q, and loss of 1p, 16q, 17p, and 22q) in FHWT by the MLPA assay
Elizabeth J. Perlman, MD
Ann & Robert H Lurie Children's Hospital of Chicago
United States: Federal Government